One of these two caregivers vaccinated in Alaska, had a serious reaction, or “anaphylactic”, requiring hospitalization.
“These individuals have been treated with appropriate medical intervention and luckily they are either cured or on the mend,” Doran Fink, of the U.S. Medicines Agency’s office of vaccines, said at a committee meeting. advisory on the authorization of another vaccine, that of Moderna.
“We are expecting more such lifts, which we will study quickly,” he added.
US authorities are liaising with UK authorities, who also use the Pfizer vaccine, to better understand these cases, he said.
“The totality of current data continues to support (the use) without further restrictions” of the Pfizer vaccine, but these cases “underscore the need to remain vigilant during the first phase of the vaccination campaign,” said Doran Fink.
To do this, “the United States Medicines Agency is working with Pfizer to pursue changes in vaccine prescribing guidelines and information, to bring attention to CDC (Centers for Disease Control and Prevention) guidelines. post-vaccination follow-up and management of immediate allergic reactions, ”he explained.
These changes will include the warning already in effect for people with a history of allergies to products contained in the vaccine, to avoid being vaccinated for now.
Facilities carrying out vaccination should also ensure that treatment for severe allergic reactions is readily available.
These warnings will also apply to the Moderna vaccine, if it receives authorization from the United States Medicines Agency.
These two remedies use a new technology, called messenger RNA (mRNA), which had never been approved in a vaccine before Pfizer.